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Group A Streptococcus (GAS) is a leading cause
of infection-related mortality in humans. All GAS
serotypes express the Lancefield group A carbohy-
drate (GAC), comprising a polyrhamnose back-
bone with an immunodominant N-acetylglucos-
amine (GlcNAc) side chain, which is the basis of
rapid diagnostic tests. No biological function has
been attributed to this conserved antigen. Here
we identify and characterize the GAC biosynthesis
genes, gacA through gacL. An isogenic mutant of
the glycosyltransferase gacI, which is defective for
GlcNAc side-chain addition, is attenuated for viru-
lence in two infection models, in association with
increased sensitivity to neutrophil killing, platelet-
derived antimicrobials in serum, and the catheli-
cidin antimicrobial peptide LL-37. Antibodies
to GAC lacking the GlcNAc side chain and con-
taining only polyrhamnose promoted opsono-
phagocytic killing of multiple GAS serotypes and
protected against systemic GAS challenge after
passive immunization. Thus, the Lancefield antigen
plays a functional role in GAS pathogenesis, and a
deeper understanding of this unique polysaccha-
ride has implications for vaccine development.Cell HINTRODUCTION
Streptococcus pyogenes, commonly known as group A Strepto-
coccus (GAS), is a preeminent human pathogen responsible
for 700 million cases of pharyngitis (‘‘strep throat’’) annually
worldwide and increasing numbers of severe invasive infections,
including necrotizing fasciitis (‘‘flesh-eating disease’’) and strep-
tococcal toxic shock syndrome (Carapetis et al., 2005). GAS
is also responsible for the postinfectious immune-mediated
disease rheumatic fever, which is a major cause of chronic heart
disease and mortality in many parts of the developing world
(Carapetis et al., 2005; Marijon et al., 2012). Serological classifi-
cation of streptococci in groups is based upon expression of
unique carbohydrate antigens in the bacterial cell wall (Lance-
field, 1928), known only to play a structural role in cell wall
biogenesis (Caliot et al., 2012; McCarty, 1952). All serotypes
of GAS express the Lancefield group A carbohydrate (GAC),
comprising a polyrhamnose backbone with an immunodomi-
nant N-acetylglucosamine (GlcNAc) side chain (McCarty, 1952,
1956); this GlcNAc epitope of GAC is the basis of all rapid diag-
nostic testing for GAS infection. Remarkably, 50% of the GAS
cell wall by weight is made up of the GAC (McCarty, 1952);
however, a specific biological function has yet to be attributed
to this conserved and abundant eponymous antigen.
Despite a high global demand (Carapetis et al., 2005), there is
currently no safe and efficacious commercial vaccine against
GAS infection. Certain unique phenotypic features of the path-
ogen pose particular challenges to vaccination (Pandey et al.,ost & Microbe 15, 729–740, June 11, 2014 ª2014 Elsevier Inc. 729
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hyaluronic acid (Kendall et al., 1937), an immunologically inert
carbohydrate ubiquitous in human connective tissues. In addi-
tion, immunodominant surface-anchored GAS M proteins are
polymorphic (>200 emm genotypes) (McMillan et al., 2013),
and regions of their dimeric coiled-coil structure may provoke
an autoimmune response against cardiac tissue in rheumatic fe-
ver (Fae´ et al., 2005). Due to its prominence in the GAS cell wall
and its conservation across all GAS serotypes, the GAC has
been considered as a potential antigen for a universal GAS vac-
cine. Passive and active mouse immunization studies with pro-
tein conjugate vaccines using purified or synthetic versions of
the wild-type (WT) GAC show significant efficacy against multi-
ple GAS serotypes (Kabanova et al., 2010; Sabharwal et al.,
2006). Moreover, anti-GAC antibodies are detected in human
serum; high titers correlate with decreased colonization in
children (Sabharwal et al., 2006) and peak around age 17, corre-
lating with dropping GAS infection rates after this age (Zimmer-
man et al., 1971). However, theoretical concerns regarding au-
toreactivity of antibodies that recognize the native GAC
GlcNAc side chain against human tissues have been raised by
several groups, but remain a point of significant controversy.
Glycoproteins from human heart valves, when used to immunize
rabbits, engender antibodies that bind to GAC in a manner
inhibited by GlcNAc (but not rhamnose and other sugars) (Gold-
stein et al., 1968), and persistence of anti-GlcNAc/GAC anti-
bodies (from 1 to 20 years) are a marker of poor prognosis of
heart valve problems in rheumatic heart disease (RHD), whereas
antibodies against streptolysin O and the polyrhamnose core of
GAC decline independently of valve complications (Ayoub et al.,
1974; Dudding and Ayoub, 1968; Shulman et al., 1974). The
specificity and persistence of elevated anti-GAC (GlcNAc) anti-
body titers for rheumatic mitral valve heart disease was also sug-
gested in a study of 30 patients versus equal-sized control
groups of control individuals, patients with congenital heart dis-
ease, and patients with nonrheumatic mitral valve prolapse (Ap-
pleton et al., 1985). Finally, anti-GlcNAc monoclonal antibodies,
cross-reactive for heart or brain tissue, have been derived from
patients with rheumatic fever and its cardiac or neurological
complications (Galvin et al., 2000; Kirvan et al., 2003).
Here, we identify the genes responsible for GAC biosynthesis,
identify a role for theGlcNAc side chain in GAS resistance to host
innate immunity, and discuss potential implications of this new
genetic insight for GAS vaccine design.
RESULTS
Identification and Mutagenesis of GAC Biosynthesis
Genes gacA through gacL
Analogous to a bioinformatic analysis of group B Streptococcus
(GBS) (Sutcliffe et al., 2008), we searched the GAS chromosome
for clusters enriched in genes encoding rhamnose polysaccha-
ride-related proteins and identified a putative 12-gene GAC
biosynthesis locus (Figure 1A) that is completely conserved
among all sequenced GAS genomes published to date. Many
of these genes, herein designated gacABCDEFGHIJKL, are
predicted to encode proteins with functional annotations as gly-
cosyltransferases (including rhamnosyltransferases) and poly-
saccharide transport proteins (Figure 1A). The same 12-gene730 Cell Host & Microbe 15, 729–740, June 11, 2014 ª2014 ElseviergacA–gacL cluster was identified in a 16 kb nonhomologous
region in two Streptococcus dysgalactiae subsp. equisimilis
(SDSE) strains from invasive human infections, which typically
express group C or G carbohydrate antigens, but showed unex-
pected reactivity to the GAS latex agglutination test (McMillan
et al., 2010) (Figures 2A–2C), implying a recent recombination
event betweenGAS and a progenitor to the SDSE strains. Similar
‘‘hybrid strains’’ have been described, but a genetic basis has
never been identified (Tanaka et al., 2008). Using a representa-
tive strain of the globally disseminated serotype M1T1 GAS
clone (5448), we performed a plasmid integrational mutagenesis
scan across the gene cluster. Nine of 12 mutants (targeting
genes gacD–gacL) were viable. Three of ninemutants (disrupting
gacI, gacJ, and gacK) lost reactivity in the diagnostic GAS latex
agglutination test (Figure 1B) and no longer interacted with
a GlcNAc-specific lectin, succinylated wheat germ agglutinin
(sWGA) (Figure 1B), indicating loss of the hallmark side chain.
Normal growth phenotypes were observed for the majority of
mutants, except those targeting gacG (putative rhamnosyltrans-
ferase), which reached lower stationary phase optical density,
and gacJ (annotated only as a membrane protein), which grew
only upon addition of 0.5 M sucrose for osmotic stabilization
(Figure S1A). Even with osmotic stabilization, we were unable
to obtain mutants in gacA, predicted to generate activated rham-
nose, nor the annotated rhamnosyltransferases gacB and gacC,
suggesting that all three genes are essential for production of the
core polyrhamnose backbone.
Glycosyltransferase GacI Is Essential for the Expression
of the GAC GlcNAc Side Chain
To study the specific role of the GlcNAc side chain in GAS
virulence phenotypes, we generated a precise in-frame allelic
replacement mutant eliminating gacI, an annotated glycosyl-
transferase. The DGacI mutant lost reactivity in the diagnostic
GAS latex agglutination test and interactionwithGlcNAc-specific
lectin sWGA (Figure 1C); both phenotypes were restored by rein-
troducing the gacI gene (marked with a silent mutation) into the
DGacI mutant chromosome, yielding the reconstituted strain
GacI* (Figure 1C). Extraction and purification of GAC from WT
GAS, DGacI, and GacI* strains followed by glycan composition
and linkage analysis unambiguously confirmed the absence of
GlcNAcsidechain in theDGacImutant, leaving thepolyrhamnose
core intact (Figures 1D and 1E; Figures S1B and S1C). Histori-
cally, ‘‘antigen-negative’’ GAS strains are known as ‘‘A-variant’’
strains and infrequently arise upon serial passage in mice and
rabbits (McCarty and Lancefield, 1955; Wilson, 1945), but have
never been isolated from humans, suggesting a crucial role for
the side chain in human infection, the only natural host of GAS.
The TarO Homolog GacO Contributes to GAC
Biosynthesis
In GBS, a neonatal pathogen, the enzyme encoded by gbcO
catalyzes the transfer of GlcNAc-1-phosphate to bactoprenyl
phosphate and is essential for synthesis of the GBS cell wall
carbohydrate (GBC) (Caliot et al., 2012). A GBS gbcO knock-
out mutant lacks cell wall rhamnose, exhibits aberrant cell
morphology and slow growth, and has impaired peptidoglycan
polymerization leading to mutanolysin hypersensitivity (Caliot
et al., 2012); all these phenotypes are reproduced in WT GBSInc.
Figure 1. Schematic Representation of the GAC Gene Cluster, Mutagenesis Scan, and DGacI Mutant
(A) Schematic representation of the GAS M1T1 strain 5448 group A carbohydrate (GAC) gene cluster M5005_Spy0602-0613, which was renamed gacA–gacL,
and annotated gene functions based on analysis using the SEED tools (http://pubseed.theseed.org).
(B) Latex agglutination reaction with GAC-specific beads and GlcNAc-specific sWGA lectin staining of viable GAS insertional knockout mutants in genes
gacD–gacL. Gray fill, medium control; black line, sWGA-FITC stain. Histogram numbers indicate geometric mean of fluorescence.
(C) Latex agglutination reaction with GAC-specific beads and GlcNAc expression as assessed by sWGA stain as indicated on GASWT, DGacI mutant, and GacI*
complemented strain.
(D and E) HPLC tracing and linkage analysis with deduced schematic structure of the repeating unit of extracted GAC from (D) GAS WT and (E) DGacI mutant
strain. See also Figure S1.
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inhibitor of gbcO-type transferases (Campbell et al., 2011).
GAS has a homolog of gbcO (MGAS5005_spy0240, gacO)
located at a distance in the chromosome from the 12-gene locus
described here. As was seen with GBS (Caliot et al., 2012), treat-
ment of WT GAS with tunicamycin inhibited growth, increased
mutanolysin sensitivity, induced aberrant morphology, and elim-
inated cell wall rhamnose (Figures 3A–3D), suggesting that gacO
is essential for synthesis of the GAC polyrhamnose core and
bacterial viability. Similar defects in cell wall integrity were not
observed with the DGacI mutant strain. To assess GAS cell
wall integrity in more depth at the functional level, we exposed
WT and DGacI mutant GAS to stresses that can disrupt a gener-
ally weakened cell wall. WT and DGacI GAS strains grew at
similar rates under high salt (up to 300 mM NaCl) and varying
pH (6.0–8.0) conditions (data not shown). The mutant showed
no increase in autolysis (Figure S2A), and killing of the DGacICell Hmutant by lysozyme or the cell wall-active antibiotics vancomy-
cin and nafcillin was even slightly slower than observed with the
parent strain (Figures S2B–S2D). Also, in contrast to tunicamy-
cin-treated GAS that completely lack GAC expression, the
DGacI mutant is not more sensitive to mutanolysin (Figure S2E)
nor defective in peptidoglycan formation asmeasured by vanco-
mycin-BODIPY labeling (Figure S2F).
Phenotypic Characterization of DGacI Expressing
GlcNAc-Deficient GAC
The isogenic DGacI mutant was compared to theWT GASM1T1
parent strain to examine the phenotypic and functional conse-
quences of loss of the GlcNAc side chain from the GAC. The
mutant and parent strains grew equally well in bacteriologic
media (Figure 4A) and did not differ with respect to well-known
virulence factors or traits including surface-anchored M1 pro-
tein expression, hyaluronic acid capsule production, fibrinogenost & Microbe 15, 729–740, June 11, 2014 ª2014 Elsevier Inc. 731
Figure 2. Streptococcus dysgalactiae subsp. equisimilis Testing Positive for GAC Possess the gacA–gacK Gene Locus
(A) Circular genome map of the group G carbohydrate expressing Streptococcus dysgalactiae subsp. equisimilis (SDSE) GGS_124 genome (accession number
AP010935) with BLAST comparisons to the completely sequenced group G carbohydrate expressing SDSE strain SDSE_D166B genome (accession number
CP002215) and the draft genomes of two SDSE strains expressing the GAC antigen, 2005-0193 and 2006-0098. The comparative map was created using BRIG.
The innermost rings show GC content (black) and GC skew (purple/green) of GGS_124. The three outer rings show BLAST comparisons (using BLASTn and an
E-value cutoff of 10.0) to SDSE_D166B (red) and to the draft genome sequences of 2005-0193 (blue) and 2006-0098 (orange). The legend shows the percent
identity of BLASTn hits to the GGS_124 reference. Both genomes share similar genome synteny with both GGS_124 and SDSE_D166B. Labels around the outer
ring refer to genomic regions present in GGS_124 but not in the two SDSE strains expressing GAC, including the GAC carbohydrate gene cluster.
(B) Genome architecture of the carbohydrate loci located between the dnaG to infC gene sequences from 2005-0193 with GGS_124 and M1 strain MGAS5005.
Regions of genetic similarity were determined using BLAST with graphical representation of syntenic gene content designated using EasyFigure 2.1. Purple
coding sequences refer to the GAC-encoded gacA–gacL cluster. Blue shaded regions between the stacked genome sequences reflect conserved gene content
with percent homology indicated by the legend.
(C) Similarity plot showing carbohydrate locus nucleotide sequence conservation between 2005-0193 versus GGS_124 (blue line) and 2005-0193 versus
MGAS5005 (green line). Evidence of homologous recombination between a GAS donor and the SDSE progenitor is evident between the gacA and pepT genes.
The plot was generated from a Clustal alignment of sequence between the dnaG and infC using a sliding window of 100 bp with values plotted as an average over
a 100 bp sliding window.
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acquisition due to streptokinase, or sugar metabolism (Figures
4B–4G). Analysis of total protein preparations by gel electropho-
resis and silver stain showed a similar pattern for WT and DGacI
mutant (Figure S3A). Interestingly, the DGacI mutant produced
longer chains in stationary phase cultures (average 16.6 cocci)
than the parent strain (average 6.7 cocci) (Figure S3B). Differ-
ences in average chain lengths were less pronounced in expo-
nential phase cultures: WT = 11.2 cocci versus DGacI = 15.6
cocci. While the elongated chains indicate a fundamental prob-
lem in cell division or chaining, transmission electronmicroscopy
of WT and DGacI revealed no apparent differences in the ultra-
structural appearance of the bacterial cell walls (Figure S3C),
findings consistent with a previous report on ‘‘A-variant’’ strains
isolated from mice (Swanson and Gotschlich, 1973).732 Cell Host & Microbe 15, 729–740, June 11, 2014 ª2014 ElsevierTheGlcNAc SideChain of GACPromotesGASSurvival in
the Presence of Whole Blood, Serum, Neutrophils, and
Antimicrobial Peptides
Since GAC is localized at the host-pathogen interface, we next
assessed survival of the DGacI mutant in assays modeling crit-
ical steps in invasive disease pathogenesis. Compared to the
WT and GacI* complemented strains, the DGacI mutant was
attenuated in whole-blood survival (Figures 5A and 5B) and
resistance to killing by isolated human neutrophils (Figure 5C),
despite similar phagocytic uptake (Figures S4A–S4C). Acceler-
ated killing of the DGacI mutant persisted in the presence
of cytochalasin D (Figures 5B and 5C), an actin microfilament
inhibitor that impairs phagocytosis. Thus, it appeared that the
DGacI mutant was sensitized to extracellular neutrophil killing,
which predominantly occurs through DNA-based neutrophilInc.
Figure 3. TarO/GbcO Homolog M5005_Spy0240 Contributes to GAC Biosynthesis
(A and B) Tunicamycin is a specific inhibitor of UDP-GlcNAC:lipid phosphate transferases like TarO and GbcO and produces a similar phenotype to a gbcO
knockout in group B Streptococcus (GBS). WT M1 GAS was treated with different concentrations of tunicamycin to inhibit the activity of homologous enzyme
encoded by the gacO gene (M5005_Spy0240), which resulted in (A) growth inhibition (mean ± SEM of four independent experiments, one-way ANOVA) and (B)
increased sensitivity to mutanolysin (100 U/ml; mean ± SEM of two independent experiments, two-way ANOVA); *p < 0.05, **p < 0.01, ***p < 0.001.
(C andD) Changes in cell morphology (C) and complete loss of rhamnose expression indicating a loss of GACproduction (D). Abbreviations: Rha, rhamnose;Man,
mannose; Glc, glucose; GlcNAc, N-acetyl-glucosamine; PS, polysaccharide; Tun, tunicamycin at indicated concentration (mg/ml). See also Figure S2.
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other antimicrobial components in human blood. Correspond-
ingly, WT GAS and DGacI mutant strains were equally suscepti-
ble to hydrogen peroxide and superoxide (Figures S4D and S4E).
Exposure of neutrophils to WT GAS and DGacI mutant strains
induced formation of NETs equally (Figure S4F); however, the
mutant was more susceptible to killing within NETs (Figure 5D)
and to the human cathelicidin antimicrobial peptide LL-37 (Fig-
ure 5E and Figure S4G). LL-37 is a component of neutrophil-spe-
cific granules important for intracellular killing and is deployed
within NETs. To examine the specific contribution of GAC and
its GlcNAc side chain in modulating LL-37 affinity for GAS, we
purified WT and mutant GAC and used surface plasmon reso-
nance to measure its interaction with the host defense peptide.
Both WT and DGacI mutant GAC bound to immobilized LL-37;
however, the binding of the DGacI mutant GAC to the host
defense peptide was substantially stronger than WT GAC at all
polysaccharide concentrations tested (Figure 5F). The calcu-
lated Kd values obtained by kinetic measurements using a 1:1
Langmuir fitting model were 130 mM for the WT GAC and
44 mM for the DGacI mutant GAC. This finding shows that theCell HGlcNAc side chain of GAC itself markedly influences LL-37 affin-
ity for its cell wall target. Increased cell surface hydrophobicity,
as measured by n-hexadecane partition of the intact bacterium,
suggested a potential basis for increased LL-37 binding and
sensitivity (Clarke et al., 2007) of the DGacI mutant (Figure 5G).
Serum, but not plasma, possesses high levels of bactericidal
activity against Gram-positive bacteria due to the presence of
platelet-derived antimicrobials that are released during the clot-
ting process (Hirsch, 1960). We initially examined baby rabbit
serum (BRS), which lacks preexisting anti-GAS antibodies. The
GAS DGacI mutant was sensitive to killing in BRS, a difference
that persisted upon heat inactivation of complement activity
(Figure 5H). Similarly, the DGacI mutant had reduced growth in
human serum (Figure 5I), but WT and mutant strains survived
equally well in human plasma (Figure 5J) and accumulated
similar levels of surface C3b (Figure 5K). Serum but not plasma
sensitivity suggested a role for platelets, important in host
defense against GAS (Hirsch, 1960; Yeaman, 2010). As inferred,
the DGacI mutant was found to be hypersensitive to killing
by the releasate of thrombin-activated washed human platelets
(Figure 5I).ost & Microbe 15, 729–740, June 11, 2014 ª2014 Elsevier Inc. 733
Figure 4. DGacI Mutant Bacteria Are Not Impaired in Expression of Several Known GAS Virulence Factors or Traits
(A–F) GAS WT and DGacI mutant bacteria were assessed for (A) growth in Todd-Hewitt broth (mean ± SD of a representative experiment); (B) M1 protein
expression (gray fill, serum control; black line, WT GAS; black dash, DGacI; gray dotted, GacI* reconstituted); (C) capsule expression in lab-grown and animal-
passaged bacteria (mean ± SEM of two independent experiments); (D) fibrinogen binding; (E) SpeB secretion; (F) plasmin accumulation of GAS WT, DGacI
mutant, and GacI*. Pooled normalized data from three independent experiments are shown (mean ± SEM; one-way ANOVA).
(G) Carbohydrate metabolism of GASWT and DGacI mutant assessed using diagnostic API 50 CH test (BioMerieux; t = 48 hr). Yellow color indicates the specific
carbohydrate is fermented, whereas blue/purple color indicates the bacteria do not metabolize the sugar. See also Figure S3.
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Virulence In Vivo
Given the increased susceptibility of the DGacI mutant to whole-
blood, neutrophil, cathelicidin, and serum (platelet-derived anti-
microbial) killing, we examined whether loss of the GlcNAc side
chain affected GAS pathogenicity in vivo. In a rabbit model of
pulmonary infection, no mortality was seen following challenge
with the DGacI mutant at a dose where the WT strain caused
89% mortality (Figure 6A). Gross and microscopic examination
of the lungs of WT GAS-infected rabbits revealed extensive
hemorrhagic necrosis amid diffuse bacterial and leukocytic
infiltrates, changes that were markedly reduced in the lungs of
surviving DGacI-infected animals (Figure 6B and Figure S5A).
Assessed early in infection (12 hr), WT GAS infection was asso-
ciated with higher fever (Figure 6C), greater bacterial load in the
lung (Figure 6D), and increased lung TNF-a levels (Figure 6E)
compared to DGacI mutant-infected rabbits. Likewise, the
DGacI mutant produced significantly lower mortality in a mouse
systemic infection model (Figure 6F), in association with lower
bacterial counts in blood (Figure 6G) and serum TNF-a levels
(Figure S5B). Thus, the GlcNAc side chain of the GAC is a viru-
lence determinant increasing bacterial survival and resistance
to host immune clearance in vivo.
The GAC Polyrhamnose Backbone Is a Vaccine Antigen
Candidate
There is a lack of consensus regarding the role of the GAC
GlcNAc side chain in the immunopathogenesis of rheumatic734 Cell Host & Microbe 15, 729–740, June 11, 2014 ª2014 Elsevierfever. Using the GlcNAc-deficient GAC extracted from DGacI
mutant bacteria as a tool, we assessed recognition of this
altered antigen by an autoreactive human monocolonal anti-
body (3B.6) derived from a patient with rheumatic carditis
that binds to heart valve and myocardium, to GAS bacteria,
and to GlcNAc-albumin, but not to albumin alone (Galvin
et al., 2000). 3B.6 showed markedly reduced binding to the
DGacI mutant carbohydrate compared to the native GAC (Fig-
ure 7A), lending support to the hypothesized role of GAC
GlcNAc in the pathogenesis of rheumatic carditis. We consid-
ered whether the GlcNAc-deficient GAC (DGAC), as purified
from the DGacI mutant, could elicit an antibody response that
facilitates opsonization and immune killing of diverse GAS sero-
types. A conjugate vaccine antigen complex, consisting of a
protein + GlcNAc-deficient GAC, was prepared using affinity in-
teractions (Zhang et al., 2013) and then used to raise a poly-
clonal rabbit anti-DGAC antiserum. The final antiserum was
highly reactive against the immunizing antigen, DGacI mutant
GAC (1:307,200, control nonimmune serum 1:1,200), as well
as the native GAC (1:307,200, control nonimmune serum
1:1,200), indicating that recognition was not shielded by pres-
ence of GlcNAc. Anti-DGAC IgG efficiently bound to intact
WT M1 GAS bacteria as well as GAS strains representing seven
additional common disease-associated serotypes (Figure 7B)
and promoted bacterial killing by human whole blood (M1)
and neutrophils (M1 + 8 additional GAS serotypes) (Figures
7C and 7D). Finally, as proof-of-concept, administration of
the anti-DGAC antiserum provided passive protection in aInc.
Figure 5. Antigen-Negative GAS Display Increased Sensitivity to Neutrophil and Platelet Immune Defenses
(A and B) DGacI mutant bacteria are defective in whole-blood proliferation both in the absence (A) and presence (B, +cytochalasin D, CytD, 25 mg/ml) of
phagocytosis. Data in (B) represent the 2 hr time point. Pooled data from three independent experiments are shown (mean ± SEM; one-way ANOVA).
(C) Total (no inhibitor) and extracellular (+Cyt D, 10 mg/ml) bacterial killing by isolated human neutrophils. Surviving cfu were quantified after 15 min and 30 min for
total killing and extracellular killing, respectively. Combined data from three independent experiments using different donors are shown (mean ± SEM; one-way
ANOVA).
(D) Survival of bacteria in neutrophil extracellular traps (NETs). Neutrophils were incubated with 25 nMPMA for 3 hr and incubated with bacteria for 30min. Pooled
data from two independent experiments are shown (mean ± SEM, one-way ANOVA).
(E) Kinetic analysis showing increased susceptibility to cathelidicin antimicrobial peptide LL-37 for the DGacI mutant compared to WT.
(F) Surface plasmon resonance (SPR) analysis. LL-37 peptide was immobilized on a CM5 sensor chip by amine coupling. Various concentrations of purified WT
(left) orDGacImutant GAC (right) were used as analytes to detect binding to LL-37. SPR sensorgramswere generated by subtraction of the reference flow cell and
the signals obtained by injection of only the running buffer from the measured response units.
(G) Increased hydrophobicity of the DGacI mutant bacteria compared to GAS WT as assessed by the n-hexadecane partition assay. The y axis indicates the
percent of original inoculum recovered from the n-hexadecane layer.
(H) Survival of GAS WT or DGacI mutant strain in 5% complement-sufficient or heat-inactivated (HI) baby rabbit serum (BRS). Survival was quantified after 5 hr
incubation at 37C. Representative data are shown.
(I) Effects of human serum or thrombin-activated platelet supernatant on survival of GAS WT or DGacI mutant bacteria. Serum and platelets were collected from
the same donor, processed as described in the Experimental Procedures, and added to a final concentration of 5% and 25%, respectively. Pooled data from five
independent experiments are shown (mean ± SEM; ratio t test). *p < 0.05, **p < 0.01, ***p < 0.001.
(J) No difference in growth of GAS WT or DGacI mutant strain in 5% human plasma (mean ± SEM, t test).
(K) C3b deposition on GAS WT and DGacI bacteria after incubation with a range of serum concentrations. Pooled data from four independent experiments are
shown (mean ± SEM). See also Figure S4.
Cell Host & Microbe
Virulence Role of the Group A Carbohydrate Antigenmurine systemic infection model with a heterologous (GAS
M49) strain (Figure 7E). Efficacy of the anti-DGAC antiserum
in promoting neutrophil opsonophagocytosis and passive im-
mune protection compared favorably to an antiserum reactive
against the WT GAC prepared through an identical procedureCell H(Figures S6A–S6C). Neither rabbit postimmune antiserum
demonstrated cross-reactivity to human cardiac antigens (Fig-
ures S6D and S6E), consistent with findings reported in postim-
mune mouse antisera against a WT GAC conjugate antigen
(Sabharwal et al., 2006).ost & Microbe 15, 729–740, June 11, 2014 ª2014 Elsevier Inc. 735
Figure 6. Loss of the GAC GlcNAc Side Chain Attenuates GAS Virulence
(A) Survival curve of rabbits infected with GASWT or DGacI mutant bacteria. Rabbits were infected with 43 109 cfu intrabronchially, and survival was monitored
for 7 days (n = 9 rabbits of either sex per group in three independent experiments; log rank test).
(B) Gross lung appearance and microscopic H&E stain of rabbit lungs after infection with GAS WT or DGacI mutant bacteria.
(C–E) Body temperature (C), lung bacterial counts (D), and lung TNF-a levels (E) in lungs of infected rabbits 12 hr after intrapulmonary challenge; n = 4 rabbits per
group; t test; mean and 95% confidence interval.
(F) Survival curve of mice upon systemic infection with GAS WT or DGacI mutant bacteria; survival was monitored for 6 days (n = 11 per group; log rank test).
(G) Blood cfu of mice 24 hr post-systemic infection (n = 10 mice per group; t test; mean and 95% confidence interval). *p < 0.05, ***p < 0.001. See also Figure S5.
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We have studied aspects of the biology of the hallmark GAC cell
wall antigen of GAS through the identification and subsequent
mutation of the genetic locus encoding its biosynthesis. An
isogenic mutant GAS strain lacking the species-defining GlcNAc
side chain had markedly reduced survival in human blood and
systemic animal infection models, with increased sensitivity to
neutrophil and serum killing identified as key elements underly-
ing the virulence attenuation. Although phagocytic uptake, com-
plement deposition, and killing of WT GAS and DGacI mutant
were similar, the mutant was hypersusceptible to human cathe-
licidin LL-37 and the antimicrobial action of factors released by
thrombin-activated platelets. Loss of the GlcNAc side chain on
GAC did not produce a general defect in GAS cell wall integrity,
as the DGacI mutant did not differ from WT in susceptibility to
autolysis, reactive oxygen species, lysozyme, nafcillin, or vanco-
mycin. GAS growth in bacteriologic media, tissue culture media,
and plasma were unaffected by loss of the GlcNAc side chain,
but the average chain length of themutant strainswas increased.
Although several well-characterized GAS virulence factors were
unaltered (e.g., M1 protein, capsule, cysteine protease, surface
plasmin acquisition), future studies may reveal additional mech-
anisms by which the GlcNAc side chain interacts with other
bacterial surface components to influence the host-pathogen
interaction. Elimination of a key structural feature of the most
abundant GAS cell wall component no doubt changes the full
context in which other GAS cell wall-associated molecules are736 Cell Host & Microbe 15, 729–740, June 11, 2014 ª2014 Elsevierdisplayed and potentially modulates their access to soluble fac-
tors, matrix components, or cellular receptors present in host
tissues. Our studies were performed in an invasive GAS isolate
representative of the globally disseminated serotype M1T1
clone, and the relative contribution of the GlcNAc side chain to
virulence might vary dependent on the quorum of other innate
immune resistance factors present in a given GAS serotype.
A variety of published clinical data, summarized in the intro-
duction, has raised concern about the potential of the
GAC GlcNAc side chain to provoke cross-reactive antibodies
relevant to the immunopathogenesis of rheumatic fever. While
anti-GlcNAc antibodies correlate with the presence and severity
of rheumatic heart disease (Ayoub et al., 1974; Dudding and
Ayoub, 1968; Shulman et al., 1974; Appleton et al., 1985), and
anti-GlcNAc monoclonal antibodies cross-reactive for heart
or brain tissue have been derived from patients with rheumatic
fever (Galvin et al., 2000; Kirvan et al., 2003), these clinical asso-
ciations have proven difficult to corroborate experimentally,
since there is no faithful animal model of rheumatic fever,
and cardiac cross-reactive antibodies are not readily elicited
in experimental immunization of mice (Sabharwal et al., 2006)
or rabbits (this study).
In 2004, the U.S. National Institute of Allergy and Infectious
Diseases convened an expert workshop of scientists, clinicians,
government agencies, and the pharmaceutical industry to review
the available data and to explore the microbiologic, immuno-
logic, epidemiologic, and economic issues involved in develop-
ment and implementation of a safe and effective GAS vaccine,Inc.
Figure 7. Antiserum Raised against GlcNAc-Deficient GAC Promotes Opsonophagocytosis of Multiple GAS Serotypes
(A) GlcNAc-specific human monoclonal antibody (mAb) 3B6 derived from a patient with rheumatic carditis (Galvin et al., 2000) shows significantly reduced
cross-reactivity with GlcNAc-deficient GAC. *p < 0.05 (t test; mean ± SEM).
(B) Binding of polyclonal anti-DGAC IgG (black line) to WT GAS of eight different disease-associated serotypes; gray fill, nonimmune rabbit IgG control. Serotype
is indicated in histogram.
(C) Enhanced killing of WT M1 GAS in human whole blood upon addition of anti-DGAC rabbit antiserum versus normal rabbit serum (NRS). Mean ± SD of a
representative experiment.
(D) Improved opsonophagocytic killing of multiple GAS serotypes by isolated human neutrophils upon addition of anti-DGAC antiserum versus NRS;
mean ± SEM, t test. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant.
(E) Mice are protected from infection withWTGASM49 through passive immunization withDGACantiserum versus NRS (n = 12 per group; log rank test). See also
Figure S6.
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Drug Administration ban on GAS vaccine research set in place
because of the suspected development of rheumatic fever in
vaccine subjects in early trials. The report summarizing the delib-
erations of the workshop (Bisno et al., 2005) stated:
Molecular mimicry—sharing of antigenic determinants be-
tween the host and antigens of GAS—has been implicated
in ARF and rheumatic heart disease and has represented
a major obstacle for vaccine development. GAS antigens,
including the M proteins and group A carbohydrate,
have been shown to contain epitopes that mediate B
and/or T cell cross-reactions with human tissue antigens.
Because the precise role of molecular mimicry in the path-
ogenesis of ARF has not been established, every effort
should bemade to exclude tissue-cross-reactive epitopes
during vaccine development.
Our proof-of-principle demonstration that antisera raised
against the polyrhamnose core of GAC, as purified from the
DGacI mutant, may still provide significant broad-spectrumCell Hopsonophagocytic activity is at minimum consistent with this
encouragement.
In summary, we have demonstrated that the classical
Lancefield antigen is not simply a structural component of the
GAS cell wall but rather an important virulence determinant.
In addition, the side chain-deficient core backbone of the
GAC, containing only the nonmammalian polyrhamnose struc-
ture and lacking the potentially autoimmune GlcNAc epitope,
merits future exploration as a component of universal GAS
vaccines.EXPERIMENTAL PROCEDURES
Bacterial Strains and Genetic Manipulations
Principal strains analyzed were GAS M1T1 5448 (Kansal et al., 2000) and M49
NZ131 (Simon and Ferretti, 1991), and Streptococcus dysgalactiae subsp.
equisimilis (SDSE) strains (2005-0193 and 2006-0098) reactive for GAC
(McMillan et al., 2010). Other GAS serotype strains were obtained from the
CDC Streptococcal Laboratory (B. Beall, Director). Insertional mutation of
gacD through gacH, and gacJ through gacL was performed as described
(Hollands et al., 2010) with osmotic protection in THB 0.5 M sucrose. Preciseost & Microbe 15, 729–740, June 11, 2014 ª2014 Elsevier Inc. 737
Cell Host & Microbe
Virulence Role of the Group A Carbohydrate Antigenin-frame allelic replacement of the gacI gene was performed using established
methodology (Pritzlaff et al., 2001). Genetic complementation of DGacI with
the gacI gene on multicopy plasmid vector pDCerm resulted in incomplete
complementation, suggesting perturbation of gene regulatory networks or
improper stoichiometry of the enzymes involved GAC biosynthesis. Therefore,
we performed genomic complementation with a ‘‘watermarked’’ copy of gacI
to allow discrimination from authentic WT cultures. Details of these techniques
are provided in the Supplemental Information.
Whole-Blood Proliferation and Phagocytosis Assay
Bacteria were incubated with lepirudin anticoagulated blood from healthy do-
nors in siliconized tubes at 37C. For vaccine-related assays, rabbit anti-WT
GAC serum, anti-DGAC serum, or nonimmune normal rabbit serum diluted
1:5 in PBS was added. Surviving colony-forming units (cfu) were quantified
by dilution plating. Cytochalasin D (25 mg/ml) was used to block phagocytosis.
Whole-blood phagocytosis was performed under shaking conditions with
FITC-labeled bacteria and analyzed by flow cytometry.
Lectin Staining, M1 Protein Expression, and IgG Binding
Overnight cultures were centrifuged and resuspended in HEPES++ buffer
(20 mM HEPES, 140 mM NaCl, 5 mM CaCl2, 2.5 mM MgCl2 [pH 7.4]) + 0.1%
bovine serum albumin (BSA) (HEPES++ 0.1% BSA) to OD600 = 0.4. The bacte-
rial suspension (100 ml) was pelleted and stained with FITC-labeled succiny-
lated wheat germ agglutinin (sWGA) to assess GlcNAc expression. M1 protein
expression was quantified on bacterial cultures at an OD600 = 0.6 using anti-
M1 or sham mouse serum and PE-conjugated anti-mouse IgG. To test IgG
binding, bacterial cultures were grown to OD600 of 0.4, washed, resuspended
in buffer, and preincubated with 10% heat-inactivated normal horse serum to
block Fc-binding proteins. After washing, samples were incubated with
0.1 mg/ml control rabbit IgG (Jackson Immunoresearch) or purified anti-
DGAC rabbit IgG followed by allophycocyanin-conjugated goat anti-rabbit
IgG. Staining was analyzed by flow cytometry.
Neutrophil Experiments
Human neutrophils were isolated from healthy donor blood using the
Polymorphprep system (Axis-Shield). Neutrophils were seeded into 96-well
flat-bottom tissue culture-treated plates (Costar) in RPMI 1640 (Invitrogen) +
2% fetal bovine serum (FBS) heat-inactivated at 70C. Bacteria were added
at a multiplicity of infection (moi) of 0.1; plates were centrifuged and incubated
at 37C with 5% CO2 for 30 min. Neutrophils were lysed and bacterial survival
(versus control wells lacking neutrophils) was determined by dilution plating.
Extracellular neutrophil killing was assessed by pretreating neutrophils with
cytochalasin D (10 mg/ml). For opsonophagocytic assays, exponential phase
bacteria were preincubated with anti-WT GAC rabbit serum, anti-DGAC rabbit
serum, or NRS diluted 1:5 in PBS and added to neutrophils at a moi of 0.1. NET
quantification was determined by counting extracellular traps after staining
with Sytox Orange. NET killing assays were performed as above with preincu-
bation of neutrophils in 25 nM phorbol 12-myristate 13-acetate (PMA) for 3 hr
to maximally induce NETs (Akong-Moore et al., 2012).
LL-37 Susceptibility
LL-37 minimum inhibitory concentrations (MICs) were determined by incu-
bating log phase cultures in DMEM 10% THB with different concentrations
of LL-37 for 24 hr at 37C. For kinetic analysis, GAS WT and DGacI mutant
bacteria were grown and resuspended as for MIC assays and incubated
with different concentrations of LL-37, and growth was recorded bymeasuring
OD600 every 30 min for 20 hr using the Bioscreen C MBR machine.
Serum, Plasma, and Platelet Survival Assays
Serum and/or plasma (lepirudin) were collected from healthy individuals and
used immediately or stored at80C. Bacterial survival in 5% serum, plasma,
or 25% platelet releasate was performed as described (Rooijakkers et al.,
2010). Survival/growth was calculated as the ratio of bacteria cfu surviving
after incubation compared to the initial inoculum.
GAC Purification and Carbohydrate Analysis
Cell pellets of bacterial strains were resuspended in cold 48% aqueous
hydrogen fluoride (HF), sonicated, and stirred at 4C for 48 hr. Next, ice-cold738 Cell Host & Microbe 15, 729–740, June 11, 2014 ª2014 ElsevierH2O was added to each bacterial suspension and the material was dialyzed
against cold H2O. Dialyzed preparations were centrifuged to remove cellular
debris, and supernatant containing polysaccharide was lyophilized. Finally,
polysaccharide (HF-PS) was purified by size-exclusion chromatography, and
positive fractions were pooled and lyophilized. Monosaccharide composition
analysis was performed using gas chromatography/mass spectrometry as
alditol acetate (AA) derivatives. Linkage analysis was performed on partially
methylated alditol acetate (PMAA) derivatives.
In Vivo Virulence
For the pulmonary infection model, rabbits (total n = 13 over four independent
experiments, either sex; eight male, five female) were infected with 43 109 cfu
of GAS WT or DGacI mutant bacteria intrabronchially, and survival was moni-
tored for 7 days (n = 9 rabbits). Lungs from a fourth cohort were harvested after
12 hr (n = 4 rabbits; twomale, two female) and homogenized for cfu counts and
TNF-a levels (ELISA, R&D Systems). For the mouse systemic infection model,
log phase bacteria were resuspended in PBS 5% porcine gastric mucin.
Female 10-week-old CD-1 mice were injected intraperitoneally (i.p.) with 2 3
106 cfu/200 ml GAS WT or DGacI mutant bacteria. Survival was monitored
twice daily for 6 days. A second group of ten CD-1 female mice was similarly
injected with GAS WT or DGacI and blood; serum and organs were harvested
at 24 hr and homogenized for bacterial cfu counts.
Preparation of WT and DGAC Protein Conjugates and Rabbit
Polyclonal Antisera
GAC purified from WT GAS (WT GAC) and the DGacI mutant (DGAC) were
coupled to recombinant pneumococcal protein SP_0435 using streptavidin-
biotin affinity interactions, and the complexes were purified by gel filtration
chromatography to > 95% purity (Zhang et al., 2013). Polyclonal rabbit anti-
bodies were raised against MAPS-conjugated WT GAC and DGAC through
Cocalico Biologicals; see Supplemental Information for details.
Mouse Passive Immunization and Challenge
Cohorts of female 10-week-old CD-1 mice (Charles River Labs) were immu-
nized i.p. with 0.5 ml anti-DGAC rabbit serum (n = 12) or normal rabbit serum
(NRS; MP Biomedicals) (n = 12) diluted 1:5 in PBS 3 hr prior to infection with
serotype M49 GAS strain NZ131. Log phase bacteria were resuspended in
PBS plus 5% porcine gastric mucin. Mice were challenged i.p. with WT M49
GAS (2.53 107 cfu/200 ml) and survival was monitored twice daily for 10 days.
Ethics Statements
Human blood and neutrophils were collected after informed consent from
healthy human volunteers as approved by the University of California San
Diego (UCSD) Human Research Protection Program. Animal infection studies
were carried out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health.
Protocols were approved by the Institutional Animal Care andUse Committees
(IACUC) at the University of Minnesota (rabbits), University of Iowa (rabbits),
and UCSD (mice). All efforts were made to minimize the suffering of animals
employed in this study.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism version 5.0d
(GraphPad Software Inc.) and display experimental data of at least two
independent experiments performed in triplicate, displaying mean and stan-
dard error of mean (SEM) throughout the manuscript, except for animal-
related experiments, which display mean ± 95% confidence intervals. The
following statistical tests were applied: comparisons between three or
more groups, one-way ANOVA; comparison between two groups, Student’s
t test; time course experiments, two-way ANOVA; animal survival curves,
log rank test. Statistical significance was accepted at p < 0.05. *p < 0.05,
**p < 0.01, ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.chom.2014.05.009.Inc.
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